

# CITATION REPORT

List of articles citing

## Economics of ramucirumab for metastatic colorectal cancer

DOI: 10.1080/14737167.2016.1259070

Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 733-745.

**Source:** <https://exaly.com/paper-pdf/64712292/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with $\alpha$ -fetoprotein concentrations of at least 400 ng/ml. <i>Journal of Medical Economics</i> , <b>2020</b> , 23, 347-352	2.4	8
1	Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3